Phase I study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Longer follow-up efficacy and safety data.
Publication
, Journal Article
Owonikoko, TK; Papadopoulos, KP; Gil-Martin, M; Moreno, V; Salama, AK; Calvo, E; Safran, H; González-Martín, A; Aljumaily, R; Mahadevan, D ...
Published in: Ann Oncol
October 2018
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Ann Oncol
DOI
EISSN
1569-8041
Publication Date
October 2018
Volume
29 Suppl 8
Start / End Page
viii461 / viii462
Location
England
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Owonikoko, T. K., Papadopoulos, K. P., Gil-Martin, M., Moreno, V., Salama, A. K., Calvo, E., … Babiker, H. M. (2018). Phase I study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Longer follow-up efficacy and safety data. Ann Oncol, 29 Suppl 8, viii461–viii462. https://doi.org/10.1093/annonc/mdy289.048
Owonikoko, T. K., K. P. Papadopoulos, M. Gil-Martin, V. Moreno, A. K. Salama, E. Calvo, H. Safran, et al. “Phase I study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Longer follow-up efficacy and safety data.” Ann Oncol 29 Suppl 8 (October 2018): viii461–62. https://doi.org/10.1093/annonc/mdy289.048.
Owonikoko TK, Papadopoulos KP, Gil-Martin M, Moreno V, Salama AK, Calvo E, et al. Phase I study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Longer follow-up efficacy and safety data. Ann Oncol. 2018 Oct;29 Suppl 8:viii461–2.
Owonikoko, T. K., et al. “Phase I study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Longer follow-up efficacy and safety data.” Ann Oncol, vol. 29 Suppl 8, Oct. 2018, pp. viii461–62. Pubmed, doi:10.1093/annonc/mdy289.048.
Owonikoko TK, Papadopoulos KP, Gil-Martin M, Moreno V, Salama AK, Calvo E, Safran H, González-Martín A, Aljumaily R, Mahadevan D, Niu J, Kal Mohan K, Li J, Stankevich E, Mathias M, Lowy I, Fury MG, Babiker HM. Phase I study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Longer follow-up efficacy and safety data. Ann Oncol. 2018 Oct;29 Suppl 8:viii461–viii462.
Published In
Ann Oncol
DOI
EISSN
1569-8041
Publication Date
October 2018
Volume
29 Suppl 8
Start / End Page
viii461 / viii462
Location
England
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis